Successes and setbacks in dual HIV/syphilis test scale-up strategies: Lessons learned for testing integration in an era of declining resources
Health Policy OPEN · 2026-06 · 10 · 100172
DOI: 10.1016/j.hpopen.2026.100172 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Policy OPEN, 2026-06. Verfasst von Aliza Monroe-Wise und 16 weiteren Autor:innen. Beteiligte Einrichtung: Global HIV, Hepatitis and STI Programmes, World Health Organization, Geneva, Switzerland. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: World Health Organization, Bill and Melinda Gates Foundation.
Abstract (Originalsprache)
With increasingly limited funding availability for global health programmes including the elimination of mother-to-child transmission of HIV, syphilis, and hepatitis B, cost-effective and cost-saving service delivery options such as service integration strategies are vital. The introduction of dual HIV/syphilis rapid diagnostic tests (RDTs) has helped bridge testing gaps by enabling immediate integration of testing for HIV and syphilis. First prequalified by WHO in 2013, widescale adoption of the dual RDTs required extensive global and national advocacy and coordination, including evidence generation, guideline development, engagement across key countries, and shifts in policies, priorities and market dynamics. Price reductions of these commodities -driven by negotiations with manufacturers-accelerated scale-up and led to broader adoption. Global Fund data indicates a rapid increase in dual RDT procurements, while country-level data shows that nations incorporating dual RDTs into antenatal care have significantly improved syphilis testing coverage which is key to eliminating congenital syphilis. Understanding the key enablers that facilitated widescale adoption of dual RDTs as well as ongoing challenges can inform rapid rollout of future multiplex testing products, which may support continued progress toward testing goals through integrated service delivery during funding decreases and shifting priorities.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Global HIV, Hepatitis and STI Programmes, World Health Organization, Geneva, Switzerland.
- Global Fund to Fight AIDS, Tuberculosis, and Malaria, Geneva, Switzerland.
- MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, UK.
- Impact Nexus Africa.
- Clinton Health Access Initiative, Boston, USA.
- The William J. Clinton Foundation, India.
Förderung
- World Health Organization
- Bill and Melinda Gates Foundation
Zitieren
APA
Monroe-Wise, A., Maman, D., Edun, O., Storey, A., Lubega, M., Carmone, A., Mungai, J., Walia, A., Bajis, S., Sistla, J., Konstantinova, A., Efronson, E., Barr-DiChiara, M., Chetty, A., Thuy Nguyen, V. T., Owiredu, M. N., & Johnson, C. C. (2026). Successes and setbacks in dual HIV/syphilis test scale-up strategies: Lessons learned for testing integration in an era of declining resources. Health Policy OPEN, 10, 100172. https://doi.org/10.1016/j.hpopen.2026.100172
Vancouver
Monroe-Wise A, Maman D, Edun O, Storey A, Lubega M, Carmone A, et al. Successes and setbacks in dual HIV/syphilis test scale-up strategies: Lessons learned for testing integration in an era of declining resources. Health Policy OPEN. 2026;10:100172. doi:10.1016/j.hpopen.2026.100172
BibTeX
@article{MonroeWise2026,
author = {Monroe-Wise, Aliza and Maman, David and Edun, Olanrewaju and Storey, Andrew and Lubega, Marvin and Carmone, Andy and Mungai, John and Walia, Arvinder and Bajis, Sahar and Sistla, Jyotsna and Konstantinova, Anna and Efronson, Emilie and Barr-DiChiara, Magdalena and Chetty, Agnes and Thuy Nguyen, Van Thi and Owiredu, Morkor Newman and Johnson, Cheryl Case},
title = {Successes and setbacks in dual HIV/syphilis test scale-up strategies: Lessons learned for testing integration in an era of declining resources},
journal = {Health Policy OPEN},
year = {2026},
volume = {10},
pages = {100172},
doi = {10.1016/j.hpopen.2026.100172}
}
EUVIMED